SLC7A5 and prostate cancer: In prostate cancer-related experiments, although downregulation of LAT1 and LAT3 in tumor cells inhibits the growth of prostate cancer cells, it remains to be determined what other mechanisms of prostate cancer resistance can be triggered by targeting LAT1 (such as activation of ATF4).